BR 108
Alternative Names: BR-108Latest Information Update: 18 Sep 2023
At a glance
- Originator BioRay Pharmaceutical
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Haematological malignancies
- Preclinical Solid tumours
Most Recent Events
- 24 May 2023 Preclinical trials in Haematological malignancies in China (Parenteral) (BioRay Pharmaceuticals pipeline, August 2023)
- 24 May 2023 Preclinical trials in Solid tumours in China (Parenteral) (BioRay Pharmaceuticals pipeline, August 2023)
- 24 May 2023 NMPA approves IND application for BR 108 in Solid tumours and Haematological malignancies